Clinical Trial Update: PD, PK, and Safety of ALTO-203 in Patients With MDD [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pharmacodynamics, pharmacokinetics, and safety of ALTO-203 in patients with Major Depressive Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• ALTO-203

Snippet

Sponsor: Alto Neuroscience | Conditions: Major Depressive Disorder, Anhedonia | Phase 2 | Status: COMPLETED